Fluorouracil costs more than you’d expect for a drug that’s been around since the 1950s. A 40-gram tube of the generic 5% topical cream averages about $363 at retail pharmacies without insurance, though discount programs can bring that below $40. The injectable form used in cancer treatment faces its own pricing pressures, driven by manufacturing complexity, recurring shortages, and a reimbursement system that discourages companies from making it. The reasons behind these prices vary depending on whether you’re dealing with the cream or the IV formulation.
Topical Fluorouracil: Brand vs. Generic Pricing
The topical cream, used to treat precancerous skin growths and some skin cancers, comes in several branded versions: Carac (0.5%), Fluoroplex (1%), Tolak (4%), and Efudex (5%). Generic versions exist for Carac and Efudex, but Tolak and Fluoroplex are still brand-name only, which keeps their prices higher. A 40-gram tube of Tolak runs about $233, while generic fluorouracil 5% cream can be found for under $39 through prescription discount programs.
That gap between the average retail price of $363 and the discount price of under $40 tells you a lot. The drug itself isn’t inherently expensive to produce. What drives the sticker price is the layered markup system of wholesalers, pharmacies, and pharmacy benefit managers that sits between the manufacturer and you. If your insurance has a high deductible or doesn’t cover the cream, you’re exposed to the full retail price rather than the much lower acquisition cost.
Injectable Fluorouracil: A Fragile Supply Chain
The injectable version, a workhorse of cancer treatment used in regimens for colorectal, breast, and other cancers, has a different cost problem. It’s a sterile injectable generic, and that category of drug is uniquely difficult to produce profitably.
According to an analysis by the U.S. Department of Health and Human Services, 70% of generic injectable drugs don’t turn a profit within three years of launch. The fixed costs of entering this market range from roughly $6 million to $12 million, covering specialized sterile manufacturing facilities, strict contamination controls, and complex formulation processes. The cost of goods sold for generic injectables runs about 42% of revenue, compared to 36% for generic pills. These tighter margins mean fewer companies bother making them. The average generic injectable has only 5 manufacturers per molecule, compared to 9 for a generic oral drug.
Fewer manufacturers means less competition, and less competition means higher prices. It also means the supply chain is fragile. If even one manufacturer hits a production snag, the remaining suppliers can’t always absorb the demand.
Shortages Push Prices Higher
Fluorouracil injection has appeared on drug shortage lists repeatedly. Manufacturers like Eugia have had vials on intermittent back order, releasing product only as it becomes available. Other suppliers have offered only short-dated vials with limited shelf life. When supply tightens, the remaining stock commands higher prices through basic economics: hospitals and clinics that need the drug for active cancer patients will pay whatever it takes to get it.
These shortages aren’t random. They’re a predictable consequence of the low-margin economics described above. When a generic injectable barely breaks even, manufacturers have little financial cushion to invest in backup production lines, extra inventory, or facility upgrades. A single equipment failure, raw material delay, or FDA compliance issue can knock a manufacturer offline for months.
Reimbursement That Doesn’t Cover Real Costs
For the injectable form, there’s another layer: the way Medicare and insurers pay for it doesn’t reflect what it actually costs to deliver. Medicare reimburses cancer drugs based on the average sales price plus a 6% markup. That formula covers the cost of the drug itself but ignores the pharmacy labor, sterile preparation, and overhead required to safely mix and dispense chemotherapy.
A microcosting study found that these pharmacy handling costs accounted for 44% to 53% of the total cost of delivering fluorouracil chemotherapy to outpatients. Hospital pharmacies must follow strict safety standards for preparing cancer drugs, including specialized equipment and trained staff. Medicare doesn’t reimburse for any of that separately. The result is that hospitals and clinics lose money dispensing low-cost chemotherapy drugs like fluorouracil, which creates pressure to either absorb the loss or shift costs elsewhere in the system.
Why a Decades-Old Drug Stays Expensive
Older drugs normally get cheaper over time as patents expire and generics flood the market. Fluorouracil has been generic for decades. But the economics work against it in several ways. The topical market sustains brand-name versions with no generic competition (Tolak, Fluoroplex) alongside generics with enormous retail markups. The injectable market has too few manufacturers, recurring shortages, and a reimbursement system that penalizes the pharmacies responsible for preparing it.
Global demand for fluorouracil is also growing. Utilization of topical fluorouracil for precancerous skin conditions has increased over time, particularly in high-income countries. Ironically, part of the reason for its popularity is that it’s considered a lower-cost treatment compared to alternatives. But “lower cost” is relative, and for uninsured or underinsured patients paying out of pocket, the price can still be a shock.
Options for Reducing Your Cost
If you’re facing a high out-of-pocket price for fluorouracil, the most effective first step is checking prescription discount programs. For the topical cream, these can cut the price from over $300 to under $40 for a 40-gram tube of the generic 5% formulation.
For injectable fluorouracil used in cancer treatment, several foundations offer copay assistance if you’re insured but struggling with out-of-pocket costs. These include CancerCare’s Co-Pay Foundation, the Patient Advocate Foundation, the HealthWell Foundation, and the Patient Access Network Foundation, among others. Each has its own eligibility requirements based on diagnosis and income. Your oncology social worker or financial counselor at your treatment center can help identify which programs you qualify for and assist with applications.
Manufacturer-sponsored copay cards are another option, though these are only available to patients with private or commercial insurance. If you have Medicare, Medicaid, or Tricare, copay cards won’t apply, but the independent foundations listed above often cover those gaps.